Welcome to our dedicated page for Ehave news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on Ehave stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ehave's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ehave's position in the market.
Ehave, Inc. (EHVVF) announced the hiring of an Institutional Review Board (IRB) to oversee its upcoming ketamine clinical trials in Miami with Tristar Wellness. This crucial step ensures the safety of participants and compliance with research protocols. The company plans to launch its KetaDASH platform for at-home ketamine therapy, aiming to enhance patient access and clinic revenues. Ehave is negotiating to franchise the KetaDASH platform across the U.S., and management highlights the potential to expand ketamine therapy research beyond mental health.
Ehave, Inc. (OTC Pink: EHVVF) announced that Dr. Bankole A. Johnson has joined its Medical Advisory Board. Dr. Johnson, a renowned psychiatrist known for his research in psychopharmacology and addiction, will advise on human trials related to cognitive and psychedelic therapies and mental health platforms. His previous roles include chairman at the University of Virginia’s Psychiatry Department and founder of Adial Pharmaceuticals. Dr. Johnson aims to integrate biological mechanisms of addiction with psychedelic medicine to improve patient care.
Ehave, a provider of digital therapeutics for mental health, announced its sponsorship of the upcoming PsyTech Summit, taking place virtually on July 19-20, 2021. The company aims to promote its KetaDASH platform, a HIPAA-compliant cloud solution for at-home ketamine infusion therapy. The summit will explore critical psychedelic topics featuring notable industry speakers. Ehave emphasizes the significance of this event for enhancing visibility and engagement in the psychedelic sector, particularly as it rolls out innovative therapeutic solutions.
Ehave, Inc. announces the addition of Dr. Muneer A. Ali to its Medical Advisory Board, effective July 1, 2021. Dr. Ali, a board-certified clinical psychiatrist and Associate Medical Director at Amen Clinics, will provide guidance on human trials for cognitive and psychedelic therapies. His expertise includes ADHD, anxiety disorders, and substance use disorders. Ehave's Chief Medical Officer highlighted Dr. Ali's invaluable insights as the company progresses in human trials. Ehave focuses on digital therapeutics to improve mental health care, leveraging blockchain technology through its flagship product, the Ehave Dashboard.
Ehave, Inc. (OTC Pink: EHVVF) has appointed Dr. Jeffrey D. Kamlet as its new Chief Medical Officer, bringing over 30 years of experience in internal medicine and addiction. This strategic hire aims to deepen clinical expertise and advance clinical studies on I.V. Ketamine treatments targeting anxiety, depression, and PTSD. Dr. Kamlet, recognized for his work in ibogaine treatment and cardiac safety, expressed enthusiasm for joining Ehave's mission to enhance mental health treatment options. Ehave continues to focus on innovative therapeutics in the mental health sector.
Ehave, Inc. (EHVVF) introduces its Medical and Vaccine Passport aimed at streamlining Covid-19 vaccination verification for small businesses. This tool enables individuals to securely manage health records and vaccination status, providing convenience as mask mandates relax. With over 150 million potential users, the upcoming Ehave Mobile App will facilitate access to electronic health records (EHRs) and billing data. The app aims to empower users to combine their health data from various sources, supporting patient-generated data to enhance healthcare engagement.
Ehave, Inc. (EHVVF) announces a licensing agreement with Health Wizz to enhance its digital health dashboard by integrating medical records management capabilities. This partnership will enable users to securely share their personal health data while ensuring HIPAA compliance. The Health Wizz mobile app, coupled with blockchain technology, aims to empower individuals to manage their health data efficiently. The global market for Electronic Health Records (EHR) is projected to reach $33.41 billion by 2025, highlighting the significance of this advancement in patient care.
Ehave, Inc. (EHVVF) has launched its KetaDASH subsidiary, introducing a HIPAA-compliant platform for at-home ketamine treatments for anxiety, depression, and PTSD.
The service aims to facilitate access to IV ketamine therapy through partnerships with clinics and healthcare providers. With studies showing that up to 85% of ketamine users experience mental health improvements, this initiative addresses the growing demand for alternative mental health solutions.
CEO Ben Kaplan emphasized the importance of providing compassionate care in a home setting.
Ehave, Inc. (EHVVF) announced the upcoming launch of KetaDASH, a groundbreaking intravenous home delivery service for ketamine therapy, expected to begin by the end of Q2 2021. This platform enables licensed clinics to treat homebound patients, potentially increasing revenue opportunities. The company has secured liability coverage and is negotiating franchising across the U.S.
Ketamine, used for pain relief, is also being studied for depression treatment. KetaDASH offers a personalized approach, connecting patients with skilled nurses for at-home care.
Ehave, Inc. (EHVVF) announced a partnership with Brain Scientific Inc. to conduct brain mapping ketamine clinical trials aimed at treating chronic pain, depression, PTSD, and other mental disorders. The trial will enroll 35 patients and start in the second half of 2021, focusing on establishing a correlation between ketamine treatment and patient improvements. Ehave aims to leverage data and AI for better mental health solutions. The trial’s primary goal is to assess safety and tolerability, with updates promised throughout the clinical process.
FAQ
What is the current stock price of Ehave (EHVVF)?
What is the market cap of Ehave (EHVVF)?
